- Home
- SRV vs KPTI Comparison
SRV vs KPTI Comparison
Compare SRV & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 172.6M |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SRV | KPTI |
|---|---|---|
| Price | $43.60 | $8.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | 61.5K | ★ 803.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $34.24 | $3.51 |
| 52 Week High | $46.40 | $10.99 |
Technical Indicators
Market Signals| Indicator | SRV | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 46.66 |
| Support Level | $42.15 | $5.60 |
| Resistance Level | $44.32 | $8.95 |
| Average True Range (ATR) | 0.75 | 0.70 |
| MACD | -0.10 | -0.21 |
| Stochastic Oscillator | 53.14 | 0.36 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).